Stryker praised for cash flow, Baker Hughes and Core Laboratories flagged as risky

Industry
โดย StockStory·Read original
Summary · why it matters

StockStory highlights Stryker as a cash-producing stock worth watching, while flagging Baker Hughes and Core Laboratories as facing challenges. Stryker's trailing 12-month free cash flow margin stands at 18.1%, with organic revenue growth averaging 9.2% over the past two years and EPS compounding at 12.2% annually over five years. Baker Hughes, with a free cash flow margin of 8.9%, has seen annual sales growth of 6.8% over five years and a gross margin of 22.1% that trails competitors. Core Laboratories, at a 3.5% free cash flow margin, posted muted 3.4% annual revenue growth over five years and a gross margin of 20.4%.

Impact on stocks 3

Energy Transition & Power Demand▼ · 1 stocks
Baker Hughes Co
BKR
▼ NegativeCapitalrelevance

Flagged as risky due to low free cash flow margin and trailing gross margin vs competitors.

Energy▼ · 1 stocks
Core Laboratories NV
CLB
▼ NegativeCapitalrelevance

Flagged as risky with low free cash flow margin and muted revenue growth.

Robotics & Physical AI▲ · 1 stocks
Stryker Corporation
SYK
▲ PositiveCapitalrelevance

Praised for strong free cash flow margin, organic revenue growth, and EPS compounding.

© 2026 MarketDXNews